A Phase 1/2a Study Evaluating the Effects of ARO-MMP7 Inhalation Solution in Healthy Subjects and Patients With Idiopathic Pulmonary Fibrosis
Latest Information Update: 09 Apr 2025
At a glance
- Drugs SRP 1002 (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Adverse reactions
- Sponsors Arrowhead Pharmaceuticals
- 04 Apr 2025 Planned End Date changed from 1 Mar 2025 to 1 Sep 2025.
- 04 Apr 2025 Planned primary completion date changed from 1 Mar 2025 to 1 Sep 2025.
- 26 Feb 2025 According to a Sarepta Therapeutics media release, this trial is one of the clinical-stage programs covered under the collaboration agreement with Arrowhead Pharmaceuticals, under which Sarepta has obtained exclusive global rights from Arrowhead to four clinical-stage and three preclinical-stage programs.